Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
TORONTO, ON / ACCESSWIRE / APRIL 2, 2024 / Lumira Ventures is delighted to announce its latest investment in Nocion Therapeutics, a clinical-stage biopharmaceutical company developing first and potentially best-in-class,...Read the Full Article
HAMILTON, ON and BOSTON, March 19, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive...Read the Full Article
TORONTO, ON / ACCESSWIRE / March 7, 2024 / Lumira Ventures, a life sciences investment firm dedicated to supporting healthcare innovation and patient impact, is proud to announce several significant advancements...Read the Full Article
Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling...Read the Full Article
Financing included participation from new and existing investors Pro forma cash and cash equivalents expected to fund current operating plan into 2027 enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or...Read the Full Article
TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP Participants treated with TPN-101 for the entire 48-week study in...Read the Full Article
A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes Endogenex, Inc., a clinical stage medical device company dedicated...Read the Full Article
Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical trials Participating investors include Roche Venture...Read the Full Article
Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection...Read the Full Article
HistoSonics, (www.histosonics.com), the manufacturer of the non-invasive Edison® Histotripsy System, announced today a patient from the University of Rochester Medical Center has received the world’s first targeted liver tumor treatments...Read the Full Article
AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round, with a new lead investor, supported...Read the Full Article
Looking to make your mark in the world of venture capital and life sciences innovation? Lumira Ventures is accepting applications for exceptional business students to join our team as a...Read the Full Article
CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion Pivotal clinical trial for lead program EG-70 targeting BCG-unresponsive non-muscle invasive bladder...Read the Full Article
Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director. Dr. Kanner joins Brent Stead, PhD, MBA, as...Read the Full Article
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a...Read the Full Article